This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo


Oral formulation of macimorelin.

Drugs List

  • GHRYVELIN 60mg granules for oral suspension sachets
  • macimorelin 60mg granules sachets sugar-free
  • Therapeutic Indications


    Growth hormone deficiency - assessment of pituitary function

    Diagnosis of growth hormone deficiency (GHD) in adults.



    Recommended dose: 500 micrograms/kg.

    Evaluate growth hormone release with three blood samples collected at 45, 60 and 90 minutes after administration.


    Children under 18 years
    Long QT syndrome
    Torsade de pointes

    Precautions and Warnings

    Family history of long QT syndrome
    Obese patients with a BMI greater than 40kg/m2
    Cardiac failure
    Electrolyte imbalance
    Glucose-galactose malabsorption syndrome
    Hepatic impairment
    History of myocardial infarction
    History of torsade de pointes
    Lactose intolerance
    Renal impairment

    Correct electrolyte disorders before treatment
    Treatment to be initiated and supervised by a specialist
    Contains lactose
    Advise patient to avoid strenuous exercise 24 hours prior to administration
    Limit fluid intake 1 hour before and 1 hour after administration
    Patient to fast for at least 8hrs prior to dose until end of blood sampling
    Perform ECG before and during treatment
    Monitor serum electrolytes
    Predisposition QT prolongation: Counsel patient on symptoms of arrhythmias
    Advise patient not to take St John's wort concurrently

    Interpretation of test results
    The maximally stimulated serum GH level of less than 2.8 nanogram/mL following administration confirms a diagnosis of adult growth hormone deficiency. Interpretation of macimorelin test results should always include the outcome of all examinations within the diagnostic work-up for the patient.

    Patients with Cushing's disease or on supra-physiologic glucocorticoid therapy (systemic doses of hydrocortisone (or equivalent) in excess of 15 mg/square meter/day) may lead to false positive results.

    Growth hormone deficiency caused by hypothalamic lesion may cause a false negative result.

    Discontinue treatment with replacement therapy with growth hormone (somatotropin) or treatment that can affect pituitary secretion of somatotropin (e.g. somatostatin analogues, clonidine, levopoda and dopamine agonists) at least 1 month before treatment.

    Ensure other deficiency affecting hormones (e.g. adrenal, thyroidal, gonadal and diabetes insipidus) are adequately replaced to exclude stimulation failure from a secondary growth hormone deficiency.

    The cut-off point for macimorelin has not been determined during the transition period of late puberty to adult maturation. Macimorelin test results were comparable to insulin tolerance test (ITT) results for patients aged 18 to 25 years.

    Pregnancy and Lactation


    Macimorelin is contraindicated during pregnancy.

    The manufacturer advises that macimorelin is not recommended during pregnancy and the risk for humans is unknown.


    Macimorelin is contraindicated during breastfeeding.

    The manufacturer advises that a decision must be made on whether to discontinued breastfeeding for the child or abstain the use of macimorelin for the woman, taking into account the benefits and risks. It is unknown whether macimorelin is excreted in human milk.

    Side Effects

    Abdominal pain
    Feeling hot
    Prolongation of QT interval
    Sensation of cold
    Sinus bradycardia
    T-wave changes


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: September 2022

    Reference Sources

    Summary of Product Characteristics: Ghryvelin 60mg granules for oral suspension in sachet. Consilient Health Limited. Revised January 2019.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.